Rosenbloom: No More Exploitation of Seniors, Taxpayers by PBMs
Published by Health Economics
Pharmacy benefit managers have long enough taken advantage seniors and taxpayers in the U.S. through strategies that exploit Medicare, Senior Care Pharmacy Coalition President/CEO Alan Rosenbloom writes in a recent article published on McKnight’s.
High costs under Medicare Part D, Rosenbloom writes, has facilitated an “anti-competitive oligopoly,” filling the pockets of conglomerates whose tendrils span across inter-related markets, including private insurers, pharmacy benefit managers and pharma chains.
“In fact, only three such conglomerates dominate the PBM market and chain pharmacies in the retail, mail order, specialty and LTC pharmacy markets, while increasingly controlling predominant Part D Plans,” Rosenbloom writes.
According to Rosenbloom, three PBMs connected to the conglomerates process some 90 percent of the prescriptions for LTC pharmacies.
“This market concentration … is stifling competition and driving up health care costs for seniors and taxpayers alike,” he writes.
Senior Care Pharmacy Coalition Applauds Chairman Comer and House Oversight Committee for Shedding Light on Harmful PBM Practices, Encourages Congress to Advance PBM Reform Legislation Heard Today in House Energy and Commerce Committee Health Subcommittee
The Senior Care Pharmacy Coalition (SCPC), the leading national voice for the long-term care pharmacy community, released a statement today regarding the House Oversight Committee’s hearing on pharmacy benefit managers.
Stuck in the middle, LTC pharmacies could be dangerously squeezed by drug price negotiations
Any lower drug prices that result from White House efforts to negotiate on behalf of Medicare beneficiaries may lead to short-term gains for nursing homes, but there also could be a steep price to pay in the long-term, experts warned this week. The Centers for Medicare & Medicaid Services on Tuesday announced the first 10 drugs covered by Medicare Part D that will be included in negotiations running through 2024. They are all commonly prescribed drugs that treat conditions ranging from diabetes to arthritis and heart failure.
Biden’s Plans to Reduce Cost of Medicare Drugs To Send Ripple Effects Through Nursing Home Industry
Following the Biden Administration’s bid this week to reduce the price of certain drugs – many of which are commonly used in nursing homes – experts are cautioning that the changes may negatively impact the bottomline of organizations in the sector. As Medicare Part D price negotiations for these drugs come into focus this week, the Senior Care Pharmacy Coalition (SCPC), for one, is warning that changes to Part D might cause “collateral damage” to long-term care pharmacies, the patients they serve and operator partners.
Stay in the Know
Get the latest news and updates on issues impacting the long-term pharmacy community.